{"id":"https://openalex.org/W2920167286","doi":"https://doi.org/10.1182/blood-2018-99-119270","title":"The Complete Dependence of Factor IX Padua (R338L) Hyperactivity on Factor VIIIa Cofactor Activity Supports Its Safety As a Transgene for Hemophilia B Gene Therapy","display_name":"The Complete Dependence of Factor IX Padua (R338L) Hyperactivity on Factor VIIIa Cofactor Activity Supports Its Safety As a Transgene for Hemophilia B Gene Therapy","publication_year":2018,"publication_date":"2018-11-29","ids":{"openalex":"https://openalex.org/W2920167286","doi":"https://doi.org/10.1182/blood-2018-99-119270","mag":"2920167286"},"language":"en","primary_location":{"id":"doi:10.1182/blood-2018-99-119270","doi":"https://doi.org/10.1182/blood-2018-99-119270","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood-2018-99-119270","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5091727998","display_name":"Benjamin J. Samelson\u2010Jones","orcid":"https://orcid.org/0000-0001-6772-4140","observed_orcids":["https://orcid.org/0000-0001-6772-4140"]},"institutions":[{"id":"https://openalex.org/I1335321130","display_name":"Children's Hospital of Philadelphia","ror":"https://ror.org/01z7r7q48","country_code":"US","type":"funder","lineage":["https://openalex.org/I1335321130"]},{"id":"https://openalex.org/I79576946","display_name":"University of Pennsylvania","ror":"https://ror.org/00b30xv10","country_code":"US","type":"education","lineage":["https://openalex.org/I79576946"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Benjamin J. Samelson-Jones","raw_affiliation_strings":["Department of Pediatrics, Division of Hematology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA","Raymond G. Perelman Center for Cellular and Molecular Therapeutics, Children's Hospital of Philadelphia, Philadelphia, PA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Pediatrics, Division of Hematology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA","institution_ids":["https://openalex.org/I79576946"]},{"raw_affiliation_string":"Raymond G. Perelman Center for Cellular and Molecular Therapeutics, Children's Hospital of Philadelphia, Philadelphia, PA","institution_ids":["https://openalex.org/I1335321130"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5035817710","display_name":"John D. Finn","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1335321130","display_name":"Children's Hospital of Philadelphia","ror":"https://ror.org/01z7r7q48","country_code":"US","type":"funder","lineage":["https://openalex.org/I1335321130"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"John D. Finn","raw_affiliation_strings":["Raymond G. Perelman Center for Cellular and Molecular Therapeutics, Children's Hospital of Philadelphia, Philadelphia, PA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Raymond G. Perelman Center for Cellular and Molecular Therapeutics, Children's Hospital of Philadelphia, Philadelphia, PA","institution_ids":["https://openalex.org/I1335321130"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5015452205","display_name":"Rodney M. Camire","orcid":"https://orcid.org/0000-0002-0585-4537","observed_orcids":["https://orcid.org/0000-0002-0585-4537"]},"institutions":[{"id":"https://openalex.org/I79576946","display_name":"University of Pennsylvania","ror":"https://ror.org/00b30xv10","country_code":"US","type":"education","lineage":["https://openalex.org/I79576946"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Rodney M. Camire","raw_affiliation_strings":["Department of Pediatrics, Division of Hematology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA","Raymond G. Perelman Center for Cellular and Molecular Therapeutics, University of Pennsylvania, Philadelphia, PA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Pediatrics, Division of Hematology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA","institution_ids":["https://openalex.org/I79576946"]},{"raw_affiliation_string":"Raymond G. Perelman Center for Cellular and Molecular Therapeutics, University of Pennsylvania, Philadelphia, PA","institution_ids":["https://openalex.org/I79576946"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5083658192","display_name":"Valder R. Arruda","orcid":"https://orcid.org/0000-0002-8100-5481","observed_orcids":["https://orcid.org/0000-0002-8100-5481"]},"institutions":[{"id":"https://openalex.org/I1335321130","display_name":"Children's Hospital of Philadelphia","ror":"https://ror.org/01z7r7q48","country_code":"US","type":"funder","lineage":["https://openalex.org/I1335321130"]},{"id":"https://openalex.org/I79576946","display_name":"University of Pennsylvania","ror":"https://ror.org/00b30xv10","country_code":"US","type":"education","lineage":["https://openalex.org/I79576946"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Valder R Arruda","raw_affiliation_strings":["Department of Pediatrics, Division of Hematology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA","Raymond G. Perelman Center for Cellular and Molecular Therapeutics, Children's Hospital of Philadelphia, Philadelphia, PA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Pediatrics, Division of Hematology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA","institution_ids":["https://openalex.org/I79576946"]},{"raw_affiliation_string":"Raymond G. Perelman Center for Cellular and Molecular Therapeutics, Children's Hospital of Philadelphia, Philadelphia, PA","institution_ids":["https://openalex.org/I1335321130"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":["https://openalex.org/A5035817710"],"corresponding_institution_ids":["https://openalex.org/I1335321130"],"apc_list":{"value":5500,"currency":"USD","value_usd":5500},"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"132","issue":"Supplement 1","first_page":"3486","last_page":"3486"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11280","display_name":"Hemophilia Treatment and Research","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11280","display_name":"Hemophilia Treatment and Research","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10613","display_name":"Virus-based gene therapy research","score":0.0005000000237487257,"subfield":{"id":"https://openalex.org/subfields/1311","display_name":"Genetics"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10746","display_name":"Platelet Disorders and Treatments","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/hemophilia-b","display_name":"hemophilia B","score":0.9139999747276306},{"id":"https://openalex.org/keywords/gene-therapy","display_name":"gene therapy","score":0.7549999952316284},{"id":"https://openalex.org/keywords/adeno-associated-virus-vectors","display_name":"adeno-associated virus vectors","score":0.8539999723434448},{"id":"https://openalex.org/keywords/thrombotic-complications","display_name":"thrombotic complications","score":0.7070000171661377},{"id":"https://openalex.org/keywords/bispecific-antibodies","display_name":"bispecific antibodies","score":0.8230000138282776},{"id":"https://openalex.org/keywords/factor-ixa","display_name":"factor IXa","score":0.33000001311302185},{"id":"https://openalex.org/keywords/factor-x","display_name":"factor X","score":0.4359999895095825},{"id":"https://openalex.org/keywords/clotting-activity","display_name":"clotting activity","score":0.48100000619888306},{"id":"https://openalex.org/keywords/hepatotoxicity","display_name":"hepatotoxicity","score":0.8809999823570251}],"concepts":[{"id":"https://openalex.org/C2781221834","wikidata":"https://www.wikidata.org/wiki/Q425360","display_name":"Factor IX","level":2,"score":0.872982382774353},{"id":"https://openalex.org/C111599444","wikidata":"https://www.wikidata.org/wiki/Q213901","display_name":"Genetic enhancement","level":3,"score":0.7966166734695435},{"id":"https://openalex.org/C2778589496","wikidata":"https://www.wikidata.org/wiki/Q487937","display_name":"Hemostasis","level":2,"score":0.6173950433731079},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.5971110463142395},{"id":"https://openalex.org/C102230213","wikidata":"https://www.wikidata.org/wiki/Q430117","display_name":"Transgene","level":3,"score":0.5640447735786438},{"id":"https://openalex.org/C2992139802","wikidata":"https://www.wikidata.org/wiki/Q179217","display_name":"Clotting factor","level":2,"score":0.5270312428474426},{"id":"https://openalex.org/C92087593","wikidata":"https://www.wikidata.org/wiki/Q427389","display_name":"Vector (molecular biology)","level":4,"score":0.4502311944961548},{"id":"https://openalex.org/C43953973","wikidata":"https://www.wikidata.org/wiki/Q7917858","display_name":"Vectors in gene therapy","level":5,"score":0.43426352739334106},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.4290789067745209},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.39986589550971985},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.39250555634498596},{"id":"https://openalex.org/C104317684","wikidata":"https://www.wikidata.org/wiki/Q7187","display_name":"Gene","level":2,"score":0.28569939732551575},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.24478411674499512},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.23455971479415894},{"id":"https://openalex.org/C40767141","wikidata":"https://www.wikidata.org/wiki/Q285697","display_name":"Recombinant DNA","level":3,"score":0.17440325021743774},{"id":"https://openalex.org/C54355233","wikidata":"https://www.wikidata.org/wiki/Q7162","display_name":"Genetics","level":1,"score":0.12060216069221497}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1182/blood-2018-99-119270","doi":"https://doi.org/10.1182/blood-2018-99-119270","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood-2018-99-119270","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.98580002784729,"id":"https://metadata.un.org/sdg/3"}],"sustainable_development_goals_aurora":[{"display_name":"Good health and well-being","score":0.6700000166893005,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2949083906","https://openalex.org/W4417006142","https://openalex.org/W2594487434","https://openalex.org/W4282825415","https://openalex.org/W2059827251","https://openalex.org/W2976260694","https://openalex.org/W4417013563","https://openalex.org/W4283662614","https://openalex.org/W4416402597","https://openalex.org/W3139291771"],"abstract_inverted_index":{"Abstract":[0],"Factor":[1],"IX":[2],"(FIX)":[3],"Padua":[4,102,117,203,288,308,325,351,371,403,419,438,453,476,501,520,531,540,553,578,611,652,662],"(R338L)":[5],"has":[6,34,241,289],"been":[7,138,242],"described":[8,243],"as":[9,244,251,532],"a":[10,38,76,211,217,245,252,275,290,330,382,533],"game":[11],"changer":[12],"for":[13,37,82,97,132,169,255,408,594,618],"hemophilia":[14,148,256],"B":[15],"(HB)":[16],"gene":[17,49,84,94,665],"therapy.":[18,85,666],"The":[19,63],"~8-fold":[20,291,405,620],"increased":[21,555,573,596],"specific":[22,199,574],"activity":[23,61,128,172,200,267,273,294,348,575,597],"compared":[24,46,204,295,326,352,477,562,623],"to":[25,47,205,229,270,296,327,353,374,378,478,563,616,624],"wild-type":[26],"FIX":[27,53,60,101,116,127,175,193,202,287,297,307,324,402,519,530,651,661],"(FIX":[28],"WT)":[29],"in":[30,145,189,207,234,329,381,395,433,444,462,481,496,599,628,663],"aPTT-based":[31],"clotting":[32,293,313,331,347],"assay":[33,332,385],"recently":[35],"allowed":[36],"lowering":[39],"of":[40,112,115,125,173,187,192,201,237,277,322,349,368,392,398,425,436,474,507,529,538,548,557,571,576,609,644,650,660,676,692],"adeno-associated":[41],"virus":[42],"(AAV)":[43],"vector":[44,66,70],"dose":[45,67],"earlier":[48],"therapy":[50,95,147],"trials":[51,96,150],"using":[52,99,210],"WT,":[54],"while":[55,551],"still":[56],"achieving":[57],"sustained":[58],"near-curative":[59],"levels.":[62],"lowered":[64],"AAV":[65,83,100],"mitigated":[68],"the":[69,108,113,122,130,170,185,190,197,235,320,345,366,390,434,470,527,569,572,595,606,619,641,648,657],"dose-dependent":[71],"hepatotoxicity,":[72],"which":[73,177],"had":[74],"remained":[75],"major":[77],"safety":[78,123,528,638],"and":[79,129,225,247,309,372,400,420,439,454,502,511,521,541,602],"efficacy":[80],"limitation":[81],"To":[86,183],"date,":[87],"at":[88],"least":[89],"2":[90],"pivotal":[91],"phase":[92],"III":[93],"HB":[98,208,283,379,396,664],"are":[103,523],"planned.":[104],"Despite":[105],"this":[106,448,490],"enthusiasm,":[107],"underlying":[109],"molecular":[110],"mechanism":[111,570],"hyperactivity":[114,191,321,473],"is":[118,167,216,248,268,303,333,356,404,414,579,592,614],"undefined.":[119],"As":[120],"such,":[121],"concerns":[124,639],"unregulated":[126],"potential":[131,642],"ensuing":[133],"thrombotic":[134,143,645],"complications":[135,144,646],"have":[136,311,456,493,504],"not":[137],"fully":[139],"addressed.":[140],"Indeed,":[141],"recent":[142],"non-gene":[146],"clinical":[149],"evaluating":[151],"non-factor":[152],"therapies":[153],"that":[154,220,319,344,389,469,499,518],"promote":[155,231],"hemostasis":[156],"by":[157,305,336,509,513],"circumventing":[158],"regulatory":[159,181],"interactions":[160],"should":[161],"engender":[162],"caution.":[163],"Activated":[164],"FVIII":[165,260,266],"(FVIIIa)":[166],"essential":[168,593],"biological":[171],"activated":[174,323,401],"(FIXa),":[176],"provides":[178],"an":[179,457,673,689],"important":[180],"requirement.":[182],"determine":[184],"role":[186],"FVIIIa":[188,238,302,338,360,413,485,544,561,613],"Padua,":[194],"we":[195,317,429,492],"measured":[196,365],"relative":[198],"WT":[206,298,310,328,355,373,421,441,455,480,503,522,542,626],"plasma":[209,265,380,397,482,629],"unique":[212],"reagent,":[213],"ACE910.":[214,340],"ACE910":[215,443,459],"bispecific":[218],"antibody":[219],"sufficiently":[221],"brings":[222],"together":[223],"FIXa":[224,437,440,452,539,552,564],"its":[226,583,587],"substrate,":[227],"FX,":[228],"efficiently":[230],"hemostasis,":[232],"even":[233],"absence":[236],"molecules.":[239],"It":[240],"\"FVIII-mimetic\"":[246],"currently":[249],"approved":[250],"bypassing":[253],"agent":[254],"A":[257],"patients":[258],"with":[259,274,339,416,442,489,560,586,612,647],"inhibitors.":[261],"In":[262,281],"our":[263],"assays,":[264],"inhibited":[269],"<1%":[271],"normal":[272],"cocktail":[276],"monoclonal":[278],"anti-FVIII":[279],"antibodies.":[280],"unadulterated":[282],"plasma,":[284],"recombinant":[285,369],"zymogen":[286,399],"higher":[292],"(Fig).":[299,315],"However,":[300,411],"when":[301,412],"replaced":[304,415],"ACE910,":[306,417],"comparable":[312,423,505],"activities":[314],"Similarly,":[316],"observe":[318,388,430],"completely":[334],"abrogated":[335],"replacing":[337],"These":[341],"results":[342,467,633],"suggest":[343],"enhanced":[346,584],"FIX(a)":[350,354,370,409,418,475,479,500,577,610,625],"wholly":[357,580],"dependent":[358,581],"on":[359,582,672,688],"cofactor":[361,486,588],"activity.":[362,487],"We":[363,387,566],"also":[364],"ability":[367],"restore":[375],"thrombin":[376,383,393,426],"production":[377],"generation":[384,394],"(TGA).":[386],"EC50":[391],"lower":[406],"than":[407],"WT.":[410,565],"demonstrate":[422,468,545],"EC50s":[424],"generation.":[427],"Importantly,":[428],"no":[431],"difference":[432],"binding":[435,460],"enzyme":[445],"kinetic":[446,536],"studies;":[447],"was":[449],"expected":[450],"because":[451],"identical":[458],"site":[461],"their":[463],"EGF-domain.":[464],"Combined,":[465,631],"these":[466,632],"~8":[471],"fold":[472],"assays":[483],"requires":[484],"Consistent":[488],"mechanism,":[491],"previously":[494,636],"observed":[495,598,627],"reconstituted":[497,601],"systems":[498],"rates":[506,547,556],"activation":[508,559],"FXIa":[510],"inactivation":[512],"antithrombin.":[514],"This":[515,590],"result":[516],"suggests":[517],"regulated":[524],"similarly,":[525],"supporting":[526],"transgene.":[534,653],"Enzyme":[535],"studies":[537],"without":[543],"similar":[546],"FX":[549,558],"activation,":[550],"demonstrates":[554],"conclude,":[567],"therefore,":[568],"interaction":[585,608],"FVIIIa.":[589],"enhancement":[591,622],"both":[600],"plasma-based":[603],"assays.":[604,630],"Moreover,":[605],"augmented":[607],"sufficient":[615],"account":[617],"pro-hemostatic":[621],"definitively":[634],"address":[635],"unanswered":[637],"regarding":[640],"risk":[643],"use":[649,659],"They":[654],"strongly":[655],"support":[656],"ongoing":[658],"Disclosures":[667],"Camire:":[668],"Pfizer:":[669],"Consultancy,":[670],"Membership":[671,687],"entity's":[674,690],"Board":[675,691],"Directors":[677,693],"or":[678,694],"advisory":[679,695],"committees,":[680],"Research":[681],"Funding;":[682],"Bayer:":[683],"Consultancy;":[684],"Spark":[685],"Therapeutics:":[686],"committees.":[696]},"counts_by_year":[],"updated_date":"2026-08-21T09:56:20.448147","created_date":"2019-03-11T00:00:00"}